The life sciences industry is critically important to the UK economy: it has a £64 billion turnover and employs more than 233,000 scientists and staff across the UK. It is also one of the most highly regulated and globally harmonised industry sectors, with a substantial proportion of the relevant regulation currently originating from membership of the EU in the form of Directives or Regulations. The impact of BREXIT is therefore critically important.
Hallam Conference Centre
44 Hallam Street
London W1W 6JJ
Wednesday, June 20, 2018
- Sir Howard Bernstein, Chair, Strategic Partnership Board, Health Innovation, Manchester
- Julia Brown, Senior Director of Healthcare, Life and Chemical Sciences, High Value Manufacturing and Health, Scottish Enterprise
- Jules Chappell OBE, Managing Director, Business, London & Partners
- Lolita Childs, Head of Quality/QP, Allergy Therapeutics (UK) Ltd
- Laura Collister, BREXIT Lead, Bioindustry Association
- Paul Fleming, Technical Director, British Generic Manufacturers Association
- Leslie Galloway, Chairman, EMIG
- Abbie Lennox, Head of Global Regulatory Strategy & Operations, RB Health
- Kath Mackay, Deputy Director of Health and Life Sciences, Innovate UK
- Dr Martin O’Kane, Head of Clinical Trials Unit, MHRA
Follow this link for the agenda.